About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 4529 record(s)
Req # A-2019-001904
Adverse Reaction Report (AER) for LEFLUNOMIDE. Report numbers: E2B_02406362, E2B_02430073, E2B_02406722, E2B_02406957, E2B_02407828, E2B_02407902, E2B_02410099, E2B_01578688, E2B_02421206, E2B_02422361, E2B_02421091, E2B_02421097, E2B_02401716,…Organization: Health Canada
April 2020
Req # A-2019-001919
Adverse Reaction Report (AER). Report numbers: 000116945, 000143149, 000226965, 000301725, 000704548.Organization: Health Canada
April 2020
Req # A-2019-001929
Adverse Reaction Report (AER) for Immunoglobulin (human). Report numbers: 000730767, E2B_02825746, E2B_02833294, E2B_02843902, E2B_02855863, E2B_02865514.Organization: Health Canada
April 2020
Req # A-2019-001985
Adverse Reaction Report (AER). Report number: 000728760.Organization: Health Canada
April 2020
Req # A-2019-002019
Adverse Reaction Report (AER). Report number: 000728386.Organization: Health Canada
April 2020
Req # A-2020-00001
Briefing notes provided to the NCC’s CEO or Chair in September, October, November and December 2019Organization: National Capital Commission
April 2020
Req # A-2019-00217
Please provide any and all communication with international data protection authorities (DPAs) between June and November 2019 regarding the effect of privacy regulation on economic development and innovation, the cost of privacy compliance for…Organization: Office of the Privacy Commissioner of Canada
April 2020
Req # A-2015-000172
All documentation regarding the establishment of bioequivalence or therapeutic or clinical equivalence of subsequent-entry inhaled respiratory medication.Organization: Health Canada
March 2020
Req # A-2018-001153
All Briefing Notes regarding the suspension and potential revocation of Agrima Botanicals Corp (Ascent Industries Corp. subsidiary) from September 1, 2018 to December 31, 2018.Organization: Health Canada
March 2020
Req # A-2018-001634
All communications plans or strategies, and consultation plans or strategies, developed to guide communications products or activities directed to the Canadian public related to the coming into force of the Cannabis Act. Timeframe: September 2016 to…Organization: Health Canada
March 2020